Could more complex molecular analysis aid biomarker-driven clinical management of poor-prognosis colorectal cancer?
New study findings provide support for the use of ctDNA to predict survival benefits and personalise treatments
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
Zoldonrasib combinations show encouraging response rates in KRAS G12D-mutant pancreatic cancer
Positive findings are reported for first-line zoldonrasib plus chemotherapy and second-line zoldonrasib plus daraxonrasib in two early-phase studies
The place for TACE combinations in hepatocellular carcinoma is still uncertain
Findings from the EMERALD-1 and EMERALD-3 studies suggest that further evidence of benefit is needed and to reflect on the use of surrogate endpoints
Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer
Tumours with no ctDNA-identified pathogenic variants for anti-EGFR drug resistance genes appear to respond to continued cetuximab beyond disease progression
New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
Is there a role for intensification immunotherapy in patients with locally advanced cervical cancer?
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer?
Long-term dostarlimab data suggest that immunotherapy may be used with curative intent in this difficult-to-treat population